MetaCap

BioLineRx (BLRX) vs Processa Pharmaceuticals (PCSA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioLineRx is the larger company by market cap ($4.8 million vs $4.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLRX-56.29%PCSA+9.86%
+42%-9%-61%
Oct 7, 20261 yearNov 20, 2026
BLRX-56.50%PCSA+2.63%
+31%-15%-61%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLRX versus PCSA key metrics
MetricBLRXPCSA
Share price$0.9639$1.56
Market cap$4.80M$4.37M
1-day change-8.20%-7.69%
YTD return-65.20%—
1-year return-70.34%—
5-year return-99.07%—
EPS (TTM)$0.00$-68.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.18M—
Revenue growth (YoY)-95.92%—
Net income (latest FY)$-2.03M$-13.56M
Gross margin80.51%—
Operating margin-871.78%—
Net margin-171.69%—
52-week high$3.95$8.88
52-week low$0.78$1.04
Distance from 52-week high-75.60%-82.43%
Analyst consensusnone—
Avg. price target upside+2182.39%—
Average volume23.43K79.50K
Shares outstanding4.98M2.80M
Employees2012
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BioLineRx

BLRX stock →

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

About Processa Pharmaceuticals

PCSA stock →

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

BLRX vs PCSA FAQ

Which is bigger, BioLineRx or Processa Pharmaceuticals?

BioLineRx (BLRX) is larger, with a market capitalization of $4.80M compared with $4.37M for Processa Pharmaceuticals (PCSA).

Are BioLineRx and Processa Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons